The opportunity cost of androgen suppression in locally advanced prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2013,（3）
• 页码范围: 356-357
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2012.166

摘要

The use of AST and radiotherapy for the treatment of locally advanced prostate cancer has become the de facto standard of care based on a rapidly accumulating body of evidence pointing to superior outcomes when the treatments are combined rather than offered in isolation.1-6 As these trials have progressed,it has become equally clear that AST carries with it a significant risk of toxicity.While some data has indicated that AST is associated with a modest increased risk in cardiovascular events,recent reports have suggested that this is unlikely to affect rates of cardiovascular death for those receiving androgen suppression as part of a curative combined-modality approach.7-9 Recent studies have focused on the QoL effects associated with such therapy including fatigue,emotional dysfunction or sexual dysfunction.